Phase III Results for Genentech's Hemlibra Published in New England Journal of Medicine

The following is an excerpt from a press release from Genentech. Read the press release in its entirety here.  Genentech, a member of the Roche Group, announced that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA®Â prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or […]

Washington Wire: August 2018

Featured Stories: HFA, along with other patient groups, continues to argue against restrictive Medicaid eligibility policies. HFA has written before about a new federal policy that allows states to cut off Medicaid coverage for adults who don’t meet state work requirements. The US Centers for Medicare and Medicaid Services has so far approved work requirements […]